Clinical Trial

Postoperative Pain Management Study

Study Description

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Exparel 266 MG Per 20 ML Injection

patients receive Exparel in bilateral TAP blocks for open abdomen surgery

Additional Information

Official Study Title

The Use of Exparel (Liposomal Bupivacaine) for Bilateral TAP (Transversus Abdominis Plane) Blocks in Open Abdomen Surgery for Postoperative Pain Control

Clinical Trial ID

NCT03878888

ParticipAid ID

b2krWd